ライフサイエンスコーパス: Candida glabrata

1 are conserved in the distantly related yeast Candida glabrata.

2 tance among some Candida species, especially Candida glabrata.

3 dida krusei, Candida tropicalis, and perhaps Candida glabrata.

4 tes of Candida, including Candida krusei and Candida glabrata.

5 ans, Candida tropicalis, Candida krusei, and Candida glabrata.

6 ortion of persisters in Candida albicans and Candida glabrata.

7 e MTI and MTII genes of the pathogenic yeast Candida glabrata.

8 d in the clinically important human pathogen Candida glabrata.

9 9% (95% CI, 99.7%-100.0%) for Candida krusei/Candida glabrata.

10 by CST using purified complexes derived from Candida glabrata.

11 nd voriconazole (from 6.1% to 18.4%) against Candida glabrata.

12 ed treatment for invasive candidiasis due to Candida glabrata.

13 rom relaxation of constraint specifically in Candida glabrata.

14 spleens of mice infected intravenously with Candida glabrata.

15 tment of bloodstream infections (BSI) due to Candida glabrata.

16 s of Candida including the distantly related Candida glabrata.

17 ent repression of RPs in the fungal pathogen Candida glabrata.

18 a eukaryotic FMNAT from the pathogenic yeast Candida glabrata.

19 attributed to trailing growth observed with Candida glabrata.

20 (DB) > white (W), similar to the result for Candida glabrata.

21 2], Mucorales [2], Fusarium species [2], and Candida glabrata [1]) occurred, representing 8.3% of pat

22 g 74 yeast isolates (14 Candida albicans, 10 Candida glabrata, 10 Candida tropicalis, 10 Candida krus

23 albicans, 14.4% Candida parapsilosis, 13.4% Candida glabrata, 10.1% Candida tropicalis, 2.4% Candida

24 lbicans (52%), Candida parapsilosis (23.7%), Candida glabrata (12.7%), Candida tropicalis (5.8%), Can

25 culture-proven infectious endophthalmitis (2 Candida glabrata, 2 coagulase-negative Staphylococcus, 1

26 5 isolates of Candida krusei, 3 isolates of Candida glabrata, 2 isolates of Saccharomyces cerevisiae

27 here were a total of 41 Candida albicans, 23 Candida glabrata, 20 Candida parapsilosis, 9 Candida tro

28 isolates of Candida (42 Candida albicans, 25 Candida glabrata, 22 Candida parapsilosis, 14 Candida tr

29 sed by Candida albicans (52.7%), followed by Candida glabrata (25.6%) and Candida tropicalis (16.3%).

30 equently isolated species (38%), followed by Candida glabrata (29%), Candida parapsilosis (17%), and

31 Common pathogens in prospective samples were Candida glabrata (36%) and C. albicans (25%).

32 he most frequently misidentified species was Candida glabrata (37% of all discrepant identifications)

33 (4 mutants), Candida krusei (3 mutants), and Candida glabrata (55 mutants).

34 icans (55.8%), Candida parapsilosis (29.4%), Candida glabrata (7.8%), and Candida tropicalis (5.6%).

35 Live Candida tropicalis, Candida glabrata, a nongerminating strain of C. albicans

36 the characterization of the SNF1 homolog of Candida glabrata, a pathogenic yeast phylogenetically re

37 heterologously expressed C. albicans ALS3 in Candida glabrata, a yeast that lacks a close ALS3 orthol

38 thogenic yeasts such as Candida albicans and Candida glabrata adhere to medical devices and form drug

39 Candida glabrata adhered avidly to human epithelial cell

40 The yeast pathogen Candida glabrata adheres avidly to cultured human epithe

41 the potentially multidrug-resistant pathogen Candida glabrata against anidulafungin and fluconazole.

42 Rapid transcriptional autoactivation of the Candida glabrata AMT1 copper metalloregulatory transcrip

43 Adherence of Candida glabrata, an opportunistic yeast pathogen, to ho

44 ere we present the structures of Atp11p from Candida glabrata and Atp12p from Paracoccus denitrifican

45 carriage, showed an increased proportion of Candida glabrata and C. tropicalis.

46 Results for Candida group and Candida glabrata and Candida krusei targets (species not

47 potentially fluconazole-resistant organisms (Candida glabrata and Candida krusei) to those with other

48 Is were due to Candida albicans, followed by Candida glabrata and Candida parapsilosis (15%), Candida

49 Categorical agreement was lowest for Candida glabrata and Candida tropicalis with both test s

50 ll as two clinically relevant yeast species (Candida glabrata and Cryptococcus neoformans), is shown.

51 meostasis in macrophages upon infection with Candida glabrata and exacerbate infection.

52 and caspofungin of 601 invasive isolates of Candida glabrata and grouped the isolates by geographic

53 ole of 559 bloodstream infection isolates of Candida glabrata and grouped the isolates by patient age

54 642 bloodstream infection (BSI) isolates of Candida glabrata and grouped the isolates by patient age

55 plies most directly to fluconazole-resistant Candida glabrata and is variable among other species of

56 red in several Candida species, most notably Candida glabrata and more recently Candida auris.

57 between four yeast strains from two species, Candida glabrata and Saccharomyces cerevisiae (haploid s

58 Comparative genomic analyses of Candida glabrata and Saccharomyces cerevisiae suggest ma

59 the Candida species group, 4% for VVC due to Candida glabrata, and 10% for T. vaginalis Sensitivity a

60 da albicans, 26 of Candida tropicalis, 23 of Candida glabrata, and 27 of other yeasts, were tested by

61 calis, Candida parapsilosis, Candida krusei, Candida glabrata, and Candida albicans).

62 Candida albicans, Candida glabrata, and Candida parapsilosis endophthalmit

63 Candida tropicalis, Candida guilliermondii, Candida glabrata, and Candida parapsilosis.

64 icans, Candida krusei, Candida parapsilosis, Candida glabrata, and Candida tropicalis as well as othe

65 da albicans, one Histoplasma capsulatum, one Candida glabrata, and one Fusarium species isolate); thr

66 es were found in CPT for Candida tropicalis, Candida glabrata, and other common pathogenic fungi.

67 th meningoencephalitis and colitis caused by Candida glabrata, and Q295* for the patient with Candida

68 -rich region of epithelial adhesin (Epa1) of Candida glabrata, and the carboxyl region of the cell wa

69 nt forms of the Tom40 protein from the yeast Candida glabrata, and truncated constructs lacking the N

70 PS on YPD-CuSO(4) is also similar to that in Candida glabrata, and we hypothesize that this is due to

71 icans, 27 Candida tropicalis, 22 Torulopsis (Candida) glabrata, and 29 other yeast isolates were test

72 The human fungal pathogen Candida glabrata appears to utilise unique stealth, evas

73 Infections with the azole-refractory yeast Candida glabrata are now commonly treated with the echin

74 Candida albicans and Candida glabrata are predominant fungi associated with o

75 Candida albicans and Candida glabrata are the 2 most prevalent Candida specie

76 r modifying genes from the pathogenic fungus Candida glabrata as well as a companion vector for compl

77 the established pathogens Candida krusei and Candida glabrata, as a species of Candida with reduced s

78 th of bacteria (Escherichia coli) and yeast (Candida glabrata) at micromolar concentrations.

79 plant recipients that developed breakthrough Candida glabrata bloodstream infections while receiving

80 ne expression by diverse microbes, including Candida glabrata, Bordetella pertussis, Escherichia coli

81 re (BC) bottles in each of ten patients with Candida glabrata BSI.

82 ich are closely related to and identified as Candida glabrata by phenotypic assays.

83 recognition of an emerging fungal pathogen, Candida glabrata, by the human NK cytotoxic receptor NKp

84 Candida albicans and Candida glabrata can be identified in blood culture bott

85 xed PCR assay detecting Candida albicans and Candida glabrata (CAN-PCR) was compared with the Affirm

86 ccharomyces from each other, as well as from Candida glabrata, Candida albicans, and Blastomyces derm

87 mplemented by the Ure2p of Candida albicans, Candida glabrata, Candida kefyr, Candida maltosa, Saccha

88 ve isolates per species of Candida albicans, Candida glabrata, Candida parapsilosis, Aspergillus fumi

89 the rRNA gene to identify Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropical

90 tible or nonsusceptible in Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropical

91 er a Candida 7-plex panel (Candida albicans, Candida glabrata, Candida tropicalis, Candida parapsilos

92 The opportunistic pathogen Candida glabrata causes significant disease in humans.

93 2 and pathogenic Candida albicans CaUpc2 and Candida glabrata CgUpc2 to AR1b and SRE/AR1c elements.

94 Candida glabrata chorioamnionitis presents unique manage

95 We hypothesized that species of the Candida glabrata clade and species with phenotypic trait

96 Candida glabrata colonization is common in patients rece

97 In addition, it is demonstrated that Candida glabrata colonizes the oral cavities of elderly

98 latively weak (28, 21, and 20% inhibition of Candida glabrata, Cryptococcus neoformans, and Escherich

99 charomyces cerevisiae and the human pathogen Candida glabrata directly bind to structurally diverse d

100 Candida glabrata emerged in the last decade as a common

101 mbers functionally identified as adhesins in Candida glabrata (Epa1, Epa6 and Epa7) bind to ligands c

102 C. albicans and Candida glabrata express the ALS (agglutinin-like sequen

103 The fungal pathogen Candida glabrata expresses a protein homologous to Ybp1

104 tion of plasma membrane protein complexes in Candida glabrata, focusing on two abundant and essential

105 e divergence of Saccharomyces cerevisiae and Candida glabrata, followed by massive gene loss that res

106 Expression microarray analysis of Candida glabrata following phagocytosis by human neutrop

107 impact of the treatment of fungemias due to Candida glabrata from a hospital perspective using three

108 he presumptive identification of Torulopsis (Candida) glabrata from other common clinical isolates of

109 resistant species, such as Candida auris and Candida glabrata, further threatens the limited armament

110 The Candida glabrata genome encodes at least 23 members of t

111 -cell interaction, the human fungal pathogen Candida glabrata harbors a large family of more than 20

112 The human pathogenic yeast Candida glabrata harbors more than 20 surface-exposed, e

113 The fungal pathogen Candida glabrata has emerged as a major health threat si

114 Candida glabrata has emerged as an important nosocomial

115 Although Candida glabrata has emerged in recent years as a major

116 Candida glabrata has emerged in recent years as a signif

117 vival, and virulence in the pathogenic yeast Candida glabrata Here, we demonstrate PI3-kinase (CgVps3

118 npoint a single species, the fungal pathogen Candida glabrata, in which a trans mutation has occurred

119 odulating organism virulence using ace2Delta Candida glabrata infection in neutropenic mice.

120 Cytokine-mediated host defense against Candida glabrata infection was compared to that against

121 o protect against neurological degeneration, Candida glabrata infection, and possibly to enhance reve

122 Vaginal Candida glabrata infections have increased significantly

123 The pathogenesis of Candida glabrata infections is poorly understood.

124 Candida glabrata is a human commensal and an opportunist

125 Candida glabrata is a major fungal pathogen notable for

126 The yeast pathogen Candida glabrata is a nicotinamide adenine dinucleotide

127 Candida glabrata is a yeast pathogen of humans.

128 The pathogenic yeast Candida glabrata is able to bind in vitro to human epith

129 The Amt1 transcription factor from Candida glabrata is activated by the formation of a tetr

130 The fungus Candida glabrata is an important and increasingly common

131 Candida glabrata is an important fungal pathogen of huma

132 Candida glabrata is an important opportunistic pathogen

133 The yeast Candida glabrata is an opportunistic pathogen of humans.

134 ctor from the opportunistic pathogenic yeast Candida glabrata is dependent on rapid metal-induced DNA

135 host colonization, the human fungal pathogen Candida glabrata is known to utilize a large family of h

136 linical impact of voriconazole resistance in Candida glabrata is not well described.

137 Candida glabrata is one of the most common causes of sys

138 gence of multidrug-resistant fungal species. Candida glabrata is the second to fourth common cause of

139 rs ACE1 (Saccharomyces cerevisiae) and AMT1 (Candida glabrata) is present in the promoters of three m

140 invasive candidiasis and candidemia due to a Candida glabrata isolate that developed resistance to al

141 We analyzed 1,598 Candida glabrata isolates for the presence of the crypti

142 The antifungal susceptibilities of 79 oral Candida glabrata isolates to fluconazole and voriconazol

143 s for testing of the susceptibilities of 235 Candida glabrata isolates to fluconazole and voriconazol

144 and echinocandin resistance were detected in Candida glabrata isolates using a whole-genome sequence.

145 ) and included 303 C. albicans isolates, 153 Candida glabrata isolates, 70 Candida tropicalis isolate

146 p to six missed episodes of candidemia (four Candida glabrata isolates, one C. albicans isolate, and

147 Candida glabrata, like Candida albicans, is an opportuni

148 We observed that the yeast Candida glabrata lost the gene encoding a phosphate-repr

149 crystal structures of the Vik1 ortholog from Candida glabrata may provide insight into this mechanism

150 /MIC(90), 0.03/0.06 mg/L; 100% susceptible), Candida glabrata (MIC(50)/MIC(90), 0.06/0.06 mg/L; 98.3%

151 st isolates were Candida albicans (n = 420), Candida glabrata (n = 112), Candida parapsilosis (n = 30

152 solates included Candida albicans (n = 161), Candida glabrata (n = 41), Candida tropicalis (n = 35),

153 s identified were Candida albicans (n = 85), Candida glabrata (n = 63), and Candida parapsilosis (n =

154 solates included Candida albicans (n = 486), Candida glabrata (n = 96), Candida tropicalis (n = 51),

155 tivity of VT-1161 against Candida krusei and Candida glabrata, pathogens that are intrinsically resis

156 ated the performance of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in sit

157 e ~28 genes, whereas in the related pathogen Candida glabrata, Pho4 has reduced Pho2 dependence and r

158 The yeast Candida glabrata rapidly autoactivates transcription of

159 albicans, heterologous expression of HYR1 in Candida glabrata rendered the organism more resistant to

160 creen assay to accurately detect isolates of Candida glabrata resistant to the azole antifungal agent

161 Also in the pathogenic fungus Candida glabrata, Rtt106 and SWI/SNF regulate drug-induc

162 Candida glabrata's ability to adhere to host tissue is m

163 We report a case of Candida glabrata sepsis associated with chorioamnionitis

164 Six yeast isolates (all Candida glabrata) showing caspofungin MIC values of >or=

165 Candida glabrata STE12 can functionally complement the n

166 The Candida glabrata STE12 homologue was cloned.

167 Candida glabrata STE12 is therefore the first virulence

168 Mutating these structures in Candida glabrata Stn1, Ten1, Pri1, and Pri2 abrogated th

169 Clinical echinocandin resistance among Candida glabrata strains is increasing, especially in th

170 nservation of this quality control system in Candida glabrata suggests that many pathogenic species o

171 C. albicans and Candida glabrata suppressed ROS production by phagocytes

172 Candida glabrata switches spontaneously at high frequenc

173 cer or fungemia caused by the DA nonproducer Candida glabrata than in patients with cancer or fungemi

174 ularly relevant for pathogenic fungi such as Candida glabrata that are closely related to S. cerevisi

175 Candida albicans and Candida glabrata that were resistant to anidulafungin, c

176 identified only 102 (82%) of 124 isolates of Candida glabrata, the predictive value of an MIS identif

177 The adherence of Candida glabrata to host cells is mediated, at least in

178 The pathogenicity of Candida glabrata to patients remains poorly understood f

179 The ability of the yeast Candida glabrata to survive copper insult requires rapid

180 Seven isolates of Candida glabrata, two isolates of Candida parapsilosis,

181 on in Saccharomyces cerevisiae, but Ure2p of Candida glabrata (Ure2(glabrata)) cannot, even though th

182 nsertional mutagenesis of the yeast pathogen Candida glabrata using the bacterial transposon Tn7.

183 d proteinase activity, play no known role in Candida glabrata virulence.

184 e CBF1 (centromere binding factor 1) gene of Candida glabrata was cloned by functional complementatio

185 dentified throughout the reading period, but Candida glabrata was difficult to differentiate from oth

186 However, Candida glabrata was the most commonly isolated species

187 nsis, a yeast species genetically related to Candida glabrata, was described following its isolation

188 rtance of SUMOylation in the human pathogen, Candida glabrata We identified the enzymes involved in s

189 d decrease the cost of the identification of Candida glabrata, we evaluated four methods for the dete

190 Known concentrations of Candida albicans and Candida glabrata were each added to a set of vials.

191 a albicans and Candida tropicalis (those for Candida glabrata were unchanged) within the 4-year span.

192 olates were echinocandin-resistant, and 9 (8 Candida glabrata) were multidrug resistant to both fluco

193 Candida glabrata, which can become resistant to fluconaz

194 The human opportunistic fungal pathogen Candida glabrata, which causes mucosal and deep-seated i

195 relative proportion of infections caused by Candida glabrata, which has reduced susceptibility to fl

196 her-level resistance has been reported among Candida glabrata, which is also frequently resistant to

197 ous proteins in Saccharomyces cerevisiae and Candida glabrata, whose sequences have diverged to a deg

198 C), and posaconazole (PSZ) in 24 isolates of Candida glabrata with decreased susceptibility to azoles